Transient hair loss in patients with chronic spontaneous urticaria treated with omalizumab.
Eur Ann Allergy Clin Immunol
; 49(6): 284-285, 2017 Nov.
Article
en En
| MEDLINE
| ID: mdl-29249138
ABSTRACT
SUMMARY:
Omalizumab (anti-IgE) is used as add-on therapy for antihistamine refractory chronic urticaria patients. The most commonly reported adverse effects were headache, arthralgia, upper respiratory infections, fatigue, nausea and injection-site reactions. However, lately a few cases of hair loss have been reported. We describe a case of transient hair loss in a young female patient after initiating treatment with omalizumab. Despite this side effect, the patient continued with omalizumab treatment for 10 months with good effect.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Urticaria
/
Antialérgicos
/
Alopecia
/
Omalizumab
/
Cabello
Tipo de estudio:
Diagnostic_studies
Límite:
Adult
/
Female
/
Humans
Idioma:
En
Revista:
Eur Ann Allergy Clin Immunol
Asunto de la revista:
ALERGIA E IMUNOLOGIA
Año:
2017
Tipo del documento:
Article